AstraZeneca, Bind team up for cancer drug delivery

AstraZeneca ($AZN) and Bind Therapeutics have joined forces in the creation of a kinase inhibitor nanotech for treating cancer, part of Bind's Accurin line of drug-delivery platforms. The collaboration gives AstraZeneca exclusive rights to the development and commercialization of the nanomedicine, while Bind will lead manufacturing. Bind stands to gain up to $69 million in upfront and preapproval funds and more than $130 million in regulatory and sales milestone payments, as well as partial royalties. Report

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…